Related Experiment Video
Updated: May 18, 2026
07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Vitamin K antagonists. Ready to be replaced?
1CardioVascular Center, University Hospital Zurich, and Institute of Physiology, Cardiovascular Research, University of Zurich, Switzerland. jan.steffel@usz.ch
Hamostaseologie
|September 8, 2012
Summary
Vitamin K antagonists (VKAs) have long been used for anticoagulation but have limitations. Novel anticoagulants offer consistent efficacy and safety for stroke prevention in atrial fibrillation and venous thromboembolism.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Vitamin K antagonists (VKAs) have been the standard for anticoagulation in atrial fibrillation (AF) and venous thromboembolism (VTE).
- VKA therapy is limited by suboptimal time in therapeutic range due to drug interactions, biological factors, and compliance issues.
Purpose of the Study:
- To review the role of VKA treatment in anticoagulation.
- To discuss the efficacy and safety of novel oral anticoagulants (NOACs) compared to VKAs.
- To evaluate the evidence for replacing VKAs with NOACs for stroke prevention in AF and VTE management.
Main Methods:
- Review of large-scale randomized clinical trials comparing NOACs (dabigatran, rivaroxaban, apixaban) with VKAs.
- Analysis of efficacy, safety, and practical advantages of NOACs.
Main Results:
- NOACs provide more consistent anticoagulation than VKAs.
- NOACs have demonstrated comparable or superior efficacy and safety in major clinical trials.
- NOACs offer advantages such as lack of mandatory monitoring and fewer drug interactions.
Conclusions:
- NOACs are effective and safe alternatives to VKAs for stroke prevention in AF and VTE treatment/prevention.
- VKAs are likely to be replaced by NOACs in most patients for these indications.
- The evidence supports a shift towards NOACs in clinical practice based on recent trial data.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Vitamins
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced in our...
01:25Role of Vitamins in Maintaining Bone Health
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:17Oxidation of Phenols to Quinones
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox property is crucial in...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox property is crucial in...